360
Participants
Start Date
May 12, 2017
Primary Completion Date
June 30, 2030
Study Completion Date
June 30, 2030
PEG-somatropin
After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing
Department of Pediatrics of Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Wuhan
Hunan Children's Hospital, Changsha
Children's Hospital of Soochow University, Naning
The First Affiated Hospital of Nanjing Medical Universit, Nanjing
Affiliated Hospital of Jiangnan University, Wuxi
Wuxi Children's Hospital, Wuxi
Jiangxi Provincial Children's Hospital, Nanchang
The First Hospital of Jilin University, Changchun
The Children's Hospital of Zhejiang University School of Medicine, Hangzhou
Shanghai Children's Hospital of Fudan University, Shanghai
Shanghai Children's Hospital, Shanghai
Tongji Hospital
OTHER
The First Hospital of Jilin University
OTHER
Affiliated Hospital of Jiangnan University
OTHER
The First Affiliated Hospital with Nanjing Medical University
OTHER
Shanghai Children's Hospital
OTHER
The Children's Hospital of Zhejiang University School of Medicine
OTHER
Children's Hospital of Fudan University
OTHER
Jiangxi Province Children's Hospital
OTHER
Hunan Children's Hospital
OTHER_GOV
Beijing Children's Hospital
OTHER
Children's Hospital of Soochow University
OTHER
Wuxi Women's & Children's Hospital
OTHER
Changchun GeneScience Pharmaceutical Co., Ltd.
INDUSTRY